Xilio Therapeutics, Inc. announced the initiation of patient dosing in Phase 2 of a clinical trial for Efarindodekin Alfa (XTX301) in patients with certain advanced solid tumors.
The company also achieved a $17.5 million development milestone under an exclusive license agreement with Gilead Sciences, Inc.
Efarindodekin Alfa (XTX301) has shown promising anti-tumor activity and a well-tolerated safety profile in Phase 1 trials.
Phase 2 Trial Initiation
Patient dosing in Phase 2 began for Efarindodekin Alfa to evaluate its efficacy in advanced solid tumors.
Development Milestone
Xilio reached a $17.5 million development milestone under the license agreement with Gilead Sciences.
Anti-Tumor Activity
Promising data from Phase 1 trials showed two partial responses in patients with advanced solid tumors.
- Efarindodekin Alfa (XTX301) demonstrates potent stimulation of anti-tumor immunity and potential to reprogram the tumor microenvironment towards an inflamed state.
- The $17.5 million milestone extends the company's cash runway, ensuring funding into the first quarter of 2027.
Xilio's progress with Efarindodekin Alfa (XTX301) in Phase 2 and the achievement of a significant development milestone underscore the potential of their tumor-activated IL-12 program.